VASO Swings to Profit on Strong Sales, Cuts Transaction Costs

TL;DR

**VASO is finally turning the corner, ditching past losses for solid revenue growth and a clean balance sheet.**

AI Summary

VASO Corp reported a significant turnaround for the three months ended September 30, 2025, achieving a net income of $1.711 million, a substantial improvement from the net loss of $1.181 million in the same period of 2024. Total revenues increased by 9.09% to $22.657 million, up from $20.769 million year-over-year. This growth was primarily driven by a 18.72% increase in professional sales services revenue, reaching $10.820 million from $9.114 million. The IT segment also saw a modest revenue increase of 1.23% to $11.218 million. For the nine months ended September 30, 2025, the company posted a net income of $0.439 million, reversing a net loss of $1.199 million in the prior year period, on total revenues of $62.076 million, up 3.92% from $59.732 million. Operating income for the quarter was $1.538 million, a stark contrast to the operating loss of $1.393 million in Q3 2024, largely due to the absence of $1.549 million in business combination transaction costs incurred in the prior year. Cash and cash equivalents rose to $34.859 million as of September 30, 2025, from $26.271 million at December 31, 2024, reflecting strong cash flow from operating activities of $9.012 million for the nine-month period.

Why It Matters

VASO Corp's return to profitability and revenue growth, particularly in professional sales services, signals a potential positive shift for investors, demonstrating improved operational efficiency and market penetration. The absence of significant business combination transaction costs, which previously weighed on earnings, suggests a clearer path to sustainable earnings. For employees, this financial stability could mean greater job security and potential for growth. Customers benefit from the continued expansion of healthcare IT and medical device offerings. In the broader market, VASO's performance in healthcare IT and medical devices highlights the ongoing demand in these sectors, potentially attracting more investment and competition.

Risk Assessment

Risk Level: medium — While VASO Corp reported a net income, its accumulated deficit remains substantial at $33.642 million as of September 30, 2025, indicating historical losses. The company's reliance on estimates for credit losses and goodwill impairment, as noted in 'NOTE B – INTERIM STATEMENT PRESENTATION', introduces a degree of financial uncertainty, as actual results could differ significantly from these estimates.

Analyst Insight

Investors should closely monitor VASO's ability to sustain its profitability and revenue growth in the coming quarters, particularly in its professional sales services segment. Evaluate the impact of new accounting standards on future financial statements and assess how the company plans to address its accumulated deficit to ensure long-term financial health.

Financial Highlights

debt To Equity

N/A

revenue

$22.657M

operating Margin

N/A

total Assets

$84.474M

total Debt

N/A

net Income

$1.711M

eps

N/A

gross Margin

N/A

cash Position

$34.859M

revenue Growth

+9.09%

Revenue Breakdown

Key Numbers

• $1.711M — Net income for Q3 2025 (Reversed a net loss of $1.181 million in Q3 2024.)
• $22.657M — Total revenues for Q3 2025 (Increased by 9.09% from $20.769 million in Q3 2024.)
• $10.820M — Professional sales services revenue for Q3 2025 (Increased by 18.72% from $9.114 million in Q3 2024.)
• $0.439M — Net income for nine months ended Sept 30, 2025 (Reversed a net loss of $1.199 million in the prior year period.)
• $62.076M — Total revenues for nine months ended Sept 30, 2025 (Increased by 3.92% from $59.732 million in the prior year period.)
• $1.538M — Operating income for Q3 2025 (Improved from an operating loss of $1.393 million in Q3 2024.)
• $34.859M — Cash and cash equivalents as of Sept 30, 2025 (Increased from $26.271 million at Dec 31, 2024.)
• $9.012M — Net cash provided by operating activities for nine months ended Sept 30, 2025 (Increased from $3.648 million in the prior year period.)
• $33.642M — Accumulated deficit as of Sept 30, 2025 (Reduced from $34.081 million at Dec 31, 2024, but still significant.)
• 175,953,035 — Shares Outstanding (As of November 10, 2025.)

Key Players & Entities

• VASO Corp (company) — registrant
• GE Healthcare Technologies, Inc. (company) — key partner for professional sales services
• Achari Ventures Holdings Corp. I (company) — former business combination partner
• VasoTechnology, Inc. (company) — IT segment subsidiary
• Vaso Diagnostics, Inc. d/b/a VasoHealthcare (company) — professional sales service segment subsidiary
• VasoMedical, Inc. (company) — equipment segment subsidiary
• EECP Global Corporation (company) — 49% minority interest investment
• Securities and Exchange Commission (regulator) — filing oversight
• FASB (regulator) — accounting standards setter
• Delaware (regulator) — state of incorporation

FAQ

Risk Factors

• Accumulated Deficit [medium — financial]: The company has an accumulated deficit of $33.642 million as of September 30, 2025. While this has reduced from $34.081 million at December 31, 2024, it indicates a history of net losses and could impact future financing or investor confidence.
• Dependence on Key Service Segments [medium — operational]: Revenue is heavily reliant on two main segments: Managed IT systems and services, and Professional sales services. A slowdown or disruption in either segment, particularly the 18.72% growth driver in professional sales services, could significantly impact overall financial performance.
• Accounts Receivable Management [low — financial]: Accounts and other receivables decreased significantly from $16.999 million at December 31, 2024, to $9.172 million at September 30, 2025. While this could indicate improved collection or reduced sales, the allowance for credit losses remains substantial at $11.767 million.
• Deferred Revenue Concentration [low — financial]: Deferred revenue, both current ($17.558 million) and long-term ($21.854 million), represents a significant portion of liabilities. Changes in customer contracts or service delivery could impact the timing of revenue recognition.
• Goodwill and Intangibles [low — operational]: The company holds $15.580 million in goodwill and $1.864 million in other intangibles. Any future impairment charges related to these assets could negatively affect net income.

Industry Context

VASO Corp operates in the IT services and sales solutions sector. The industry is characterized by rapid technological advancements and evolving client needs, requiring continuous adaptation. Competition is often driven by service quality, specialized expertise, and pricing. The shift towards managed IT services and specialized sales support reflects a broader trend of companies outsourcing complex functions to focus on core competencies.

Regulatory Implications

As a publicly traded company, VASO Corp is subject to SEC regulations and accounting standards (GAAP). Compliance with financial reporting requirements is crucial. Potential risks could arise from changes in data privacy regulations (e.g., GDPR, CCPA) if IT services involve handling sensitive client data, and from evolving tax laws impacting revenue recognition or operational costs.

What Investors Should Do

1. Monitor the sustainability of professional sales services growth.
2. Analyze the reduction in accounts and other receivables.
3. Evaluate the impact of deferred revenue on future earnings.
4. Assess the company's path to eliminating the accumulated deficit.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net income of $1.711 million on revenues of $22.657 million, a significant turnaround from Q3 2024.
• 2025-09-30: End of Nine Months 2025 — Achieved net income of $0.439 million on revenues of $62.076 million, reversing prior year losses.
• 2025-09-30: Cash and cash equivalents balance — Stood at $34.859 million, up from $26.271 million at year-end 2024, indicating strong cash generation.
• 2024-09-30: End of Q3 2024 — Reported a net loss of $1.181 million and an operating loss of $1.393 million.
• 2024-12-31: Year-end 2024 — Cash and cash equivalents were $26.271 million.

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company's historical profitability and its current financial standing, despite recent improvements.)

Deferred revenue

Revenue that has been received by a company but not yet earned, typically because the goods or services have not yet been delivered or rendered. (Represents future revenue obligations and impacts the timing of income recognition.)

Allowance for credit losses

An estimate of the amount of accounts receivable that a company expects will not be collected. (Impacts the net realizable value of receivables and reflects the risk of non-payment by customers.)

Goodwill

An intangible asset that arises when one company acquires another for a price greater than the fair market value of its identifiable net assets. (Represents a significant portion of the company's assets and is subject to impairment testing.)

Business combination transaction costs

Expenses incurred when a company merges with or acquires another company. (These costs can significantly impact reported operating income in the period they are incurred, as seen in the prior year's Q3 results.)

Year-Over-Year Comparison

VASO Corp has demonstrated a significant financial turnaround compared to the prior year. Total revenues for Q3 2025 increased by 9.09% year-over-year to $22.657 million, driven by an impressive 18.72% surge in professional sales services revenue. This top-line growth, coupled with the absence of significant prior-year business combination transaction costs ($1.549 million), resulted in a swing from a $1.393 million operating loss to a $1.538 million operating income. Consequently, net income for the quarter was $1.711 million, a substantial improvement from the $1.181 million net loss in Q3 2024. Cash reserves also strengthened, with cash and cash equivalents rising to $34.859 million from $26.271 million at year-end 2024.

Filing Documents

• ea0264357-10q_vaso.htm (10-Q) — 815KB
• ea026435701ex31-1_vaso.htm (EX-31.1) — 10KB
• ea026435701ex31-2_vaso.htm (EX-31.2) — 10KB
• ea026435701ex32-1_vaso.htm (EX-32.1) — 4KB
• ea026435701ex32-2_vaso.htm (EX-32.2) — 4KB
• image_001.jpg (GRAPHIC) — 8KB
• 0001213900-25-110955.txt ( ) — 5159KB
• vaso-20250930.xsd (EX-101.SCH) — 44KB
• vaso-20250930_cal.xml (EX-101.CAL) — 51KB
• vaso-20250930_def.xml (EX-101.DEF) — 192KB
• vaso-20250930_lab.xml (EX-101.LAB) — 373KB
• vaso-20250930_pre.xml (EX-101.PRE) — 217KB
• ea0264357-10q_vaso_htm.xml (XML) — 747KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1

- FINANCIAL STATEMENTS

ITEM 1 - FINANCIAL STATEMENTS 1 CONDENSED CONSOLIDATED BALANCE SHEETS as of September 30, 2025 (unaudited) and December 31, 2024 1 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 2 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) for the Nine Months Ended September 30, 2025 and 2024 4 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) 5

- MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 18

- Quantitative and Qualitative Disclosures About Market Risk

ITEM 3 - Quantitative and Qualitative Disclosures About Market Risk. 25

- CONTROLS AND PROCEDURES

ITEM 4 - CONTROLS AND PROCEDURES 25

- OTHER INFORMATION

PART II - OTHER INFORMATION 26

– LEGAL PROCEEDINGS

ITEM 1 – LEGAL PROCEEDINGS 26

Risk Factors

ITEM 1A. Risk Factors. 26

Unregistered Sales of Equity Securities and Use of Proceeds

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds. 26

Defaults Upon Senior Securities

ITEM 3. Defaults Upon Senior Securities. 26

Mine Safety Disclosures

ITEM 4. Mine Safety Disclosures. 26

Other Information

ITEM 5. Other Information. 26

– EXHIBITS

ITEM 6 – EXHIBITS 27 Page i

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

- FINANCIAL STATEMENTS

ITEM 1 - FINANCIAL STATEMENTS Vaso Corporation and Subsidiaries CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) September 30, 2025 December 31, 2024 (unaudited) ASSETS CURRENT ASSETS Cash and cash equivalents $ 34,859 $ 26,271 Accounts and other receivables, net of an allowance for credit losses and commission adjustments of $ 11,767 at September 30, 2025 and $ 10,708 at December 31, 2024 9,172 16,999 Receivables due from related parties 1,122 943 Inventories, net 893 911 Deferred commission expense 3,414 3,659 Prepaid expenses and other current assets 2,445 2,402 Total current assets 51,905 51,185 Property and equipment, net of accumulated depreciation of $ 10,666 at September 30, 2025 and $ 10,712 at December 31, 2024 1,405 1,544 Operating lease right of use assets 1,750 2,345 Goodwill 15,580 15,551 Intangibles, net 1,864 1,615 Other assets, net 6,742 5,358 Investment in EECP Global 324 436 Deferred tax assets, net 4,904 4,904 Total assets $ 84,474 $ 82,938 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $ 3,947 $ 4,179 Accrued commissions 1,800 3,256 Accrued expenses and other liabilities 6,298 8,251 Finance lease liabilities - current - 24 Operating lease liabilities - current 974 1,067 Sales tax payable 736 802 Income taxes payable - 60 Deferred revenue - current portion 17,558 17,072 Notes payable - current portion 281 6 Due to related party 3 3 Total current liabilities 31,597 34,720 LONG-TERM LIABILITIES Operating lease liabilities, net of current portion 776 1,278 Deferred revenue, net of current portion 21,854 17,822 Other long-term liabilities 2,011 1,416 Total long-term liabilities 24,641 20,516 COMMITMENTS AND CONTINGENCIES (NOTE O) STOCKHOLDERS' EQUITY Preferred stock, $ .01 par value; 1,000,000 shares authorized; nil shares issued and outst

View Full Filing

View this 10-Q filing on SEC EDGAR